-
MK-0812 for CCR2 and MASH Research
2026-09-14
Use MK-0812 to isolate CCR2-dependent monocyte trafficking from the gut–liver mechanisms implicated in MASH. This workflow combines human whole-blood pharmacology, immune-cell flow cytometry, chemotaxis assays, and TM6SF2-centered mouse models to connect target engagement with tissue inflammation.
-
Phenothiazines, ROS, and Macrophage Antibacterial Defense
2026-09-14
Qiu et al. show that phenothiazines strengthen macrophage antibacterial activity through increased lysosomal activity, reactive oxygen species (ROS), and autophagy. Pharmacological inhibition of autophagy or ROS weakened the response, while perphenazine reduced pathology in a Salmonella Typhimurium infection model, supporting phenothiazines as host-directed therapy leads.
-
Chloroquine Workflows for Autophagy and Cancer Research
2026-09-13
Build reproducible Chloroquine experiments around lysosomal pH, autophagic flux, inflammatory signaling, and orthogonal cancer readouts. This guide translates the TQB3720 ferroptosis study into practical assay choices without confusing a mechanistic comparator with proof of Chloroquine activity.
-
SB 431542: From ALK5 Biology to Translation
2026-09-12
A translational guide to using SB 431542 as an ALK5 inhibitor, connecting TGF-β/Smad2 biology, glioma and tumor-immunity evidence, and a human iPSC-derived sensory-neuron model for disciplined experimental strategy.
-
Ruxolitinib Phosphate: From JAK Signals to Cell Fate
2026-09-11
Ruxolitinib phosphate (INCB018424) offers translational researchers a precise way to interrogate JAK1/JAK2-dependent cytokine biology, while emerging evidence in anaplastic thyroid carcinoma connects JAK/STAT signaling pathway modulation to mitochondrial dynamics, apoptosis, and GSDME-dependent pyroptosis. This article translates that mechanistic insight into practical study design, product-handling guidance, and a framework for evaluating pathway inhibitors beyond conventional product-page claims.
-
NF 340: P2Y11 Antagonist for Invasion Biology
2026-09-11
Explore how the P2Y11 antagonist NF 340 helps test the QPRT–purinergic signaling axis in breast cancer invasion. This evidence-centered guide connects receptor perturbation with assay design, mechanistic interpretation, and experimental limitations.
-
NF 340 P2Y11 Antagonist Workflow
2026-09-10
Use NF 340 as a receptor-level tool to test how P2Y11 signaling connects QPRT activity with breast cancer cell motility and myosin light-chain phosphorylation. This guide combines dose-finding, pathway controls, phospho-readouts, and invasion assays while clearly separating established evidence from practical extensions into immunology research.
-
MEHP, AhR, and Ovarian Follicle Toxicity
2026-09-10
A 2024 Biology of Reproduction study identifies aryl hydrocarbon receptor activation as a functional mediator of mono(2-ethylhexyl) phthalate toxicity in mouse ovarian antral follicles. Pharmacological blockade with CH 223191 partially restored follicle growth, estrogen production, and estrogen-responsive gene expression, providing a useful mechanistic framework for reproductive environmental toxicology research.
-
Aminopeptidase Selectivity in ACE Inhibitor Research
2026-09-09
The 1992 reference study directly compared how bestatin, aminopeptidase inhibitors, and several ACE-inhibitor chemotypes affect the cell-surface zinc aminopeptidases AP-A, AP-N, and AP-W. Its central contribution is a clearer separation of inhibitor selectivity, showing that some biological or clinical effects attributed to a compound may reflect activity at an unintended aminopeptidase.
-
TAK-242 Workflow for TLR4 Inflammation Studies
2026-09-09
TAK-242 (Resatorvid) gives researchers a selective way to interrogate TLR4-dependent inflammation, from LPS-stimulated macrophages to neuroinflammation models. This practical guide connects dose planning, cytokine readouts, rat-study precedent, and troubleshooting for more reproducible pathway studies.
-
Ruxolitinib Phosphate: JAK/STAT Assay Workflows
2026-09-08
Ruxolitinib phosphate (INCB018424) supports controlled JAK1/2 inhibition across cytokine signaling, inflammatory, and tumor-cell assays. This guide translates a recent anaplastic thyroid carcinoma study into practical workflows for pathway validation, mitochondrial-death profiling, and troubleshooting.
-
SB 431542: ALK5 Inhibitor Workflows for LUAD
2026-09-08
SB 431542 provides a practical receptor-level way to interrogate canonical TGF-β signaling in lung adenocarcinoma, glioma, and immune-cell assays. This guide translates pathway biology into controlled dosing, Smad2 readouts, phenotype validation, and troubleshooting strategies without confusing pathway inhibition with proof of a single downstream mechanism.
-
L. plantarum P101 and AMPK in Alcoholic Steatosis
2026-09-07
A 2025 mouse study shows that Lactiplantibacillus plantarum P101 reduced alcohol-induced hepatic lipid accumulation in association with AMPK activation. Pharmacological AMPK inhibition weakened these effects, while gut microbiota profiling and serum metabolomics identified microbial taxa and stercobilinogen as candidate components of the gut–liver mechanism.
-
Capsaicin, Autophagy, and BMSC Protection
2026-09-07
The reference study shows that capsaicin preserves rat bone marrow stromal cell viability and osteogenic differentiation during hydrogen peroxide-induced oxidative stress. Its mechanistic contribution is the proposed link between TRPV1-dependent calcium influx, autophagy activation, and altered PI3K/AKT/mTOR phosphorylation, providing a testable framework for studying BMSC dysfunction in osteoporosis.
-
Prednisone (B2148): Reliable Cell Assays
2026-09-05
This scenario-driven guide explains how Prednisone (SKU B2148) can improve experimental consistency in lymphocyte viability, proliferation, and apoptosis assays. It covers mechanism, DMSO formulation, protocol controls, data interpretation, and practical supplier selection for biomedical laboratories.